EYPT

Key Statistics

Latest News

Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates

Zacks 1 day ago

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

GlobeNewswire 2 days ago

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire 3 days ago

A Look At EyePoint Pharmaceuticals (EYPT) Valuation As Models Suggest A Large Gap To Fair Value

Simply Wall St. Feb 19, 2026

EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?

Zacks Feb 18, 2026

Community Sentiment

Sign in to vote

0 votes

Discussion (0)

About EyePoint, Inc.

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.